bioAffinity Technologies, Inc., a biotech firm focused on developing noninvasive diagnostic tools for lung cancer and other pulmonary conditions, has announced its participation at CHEST 2025, the annual conference hosted by the American College of Chest Physicians. The company will present research that validates the procedures used to collect and transport patient samples for their CyPath Lung test, a noninvasive method designed to detect early-stage lung cancer.
Health Technology Insights: John D’Angelo Named CEO of Northwell Health
Maria Zannes, President and CEO of bioAffinity Technologies, emphasized the importance of the research, explaining that it highlights the thorough scientific approach behind every stage of the CyPath Lung process. She noted that this rigor is what allows the test to provide dependable and timely results when patients need them most. Zannes expressed pride in sharing their findings at CHEST, a leading forum that gathers top pulmonary experts to explore innovative technologies like CyPath Lung.
Health Technology Insights: NextGen Healthcare Completes CEO Transition Ahead of Annual User Group Meeting
Rossella Titone, PhD, the project manager for product development at bioAffinity, will be presenting a poster titled “The Effect of Sputum Storage and Shipping Temperature on Flow Cytometric Outcomes of Sputum-Based Diagnostic Tests.” Her presentation is scheduled for October 22, 2025, at 10:20 a.m. at poster board number 4324. This research examines how different handling conditions impact the quality of sputum samples used for diagnostic testing, supporting the company’s current protocols for collecting clinical specimens at home and shipping them back to the lab.
Dr. Gordon Downie, MD, PhD, Chief Medical Officer at bioAffinity Technologies, commented that their approach allows physicians to receive patient results within two days. He highlighted recent case studies demonstrating the test’s ability to identify lung cancer at the potentially curable Stage 1A, underscoring the clinical significance of the research Dr. Titone will present. Dr. Downie expressed enthusiasm for engaging with healthcare professionals at CHEST to discuss how CyPath® Lung offers a valuable tool for improving patient outcomes through early detection.
Health Technology Insights: Cynosure Lutronic Redefines Skin Resurfacing with the Launch of the eCO2 3D Laser
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
